Adjuvants for Coronavirus Vaccines

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Adjuvants are crucial for enhancing immune responses in subunit and inactivated vaccines.
• Previous coronavirus vaccine development (SARS-CoV, MERS-CoV) has explored limited adjuvants like aluminum salts, emulsions, and TLR agonists.
• There is a notable gap in understanding the specific effects and efficacy of adjuvants in coronavirus vaccines.

Purpose of the Study:

• To provide a comprehensive overview of adjuvants employed in reported coronavirus vaccine studies.
• To identify key adjuvants used in vaccines against SARS-CoV, MERS-CoV, and SARS-CoV-2.
• To guide the selection of adjuvants with optimal efficacy and safety for COVID-19 vaccine development.

Main Methods:

• Literature review of published coronavirus vaccine studies.
• Analysis of adjuvant types formulated in experimental and pre-clinical vaccine candidates.
• Synthesis of information on adjuvant use across different coronavirus vaccine platforms.

Main Results:

• Aluminum salts, emulsions, and TLR agonists are the most frequently reported adjuvants in coronavirus vaccine research.
• Evidence on the specific impact and comparative effectiveness of these adjuvants in coronavirus vaccine contexts remains limited.
• The current landscape shows a reliance on established adjuvant classes with ongoing research into their specific roles.

Conclusions:

• A thorough understanding of adjuvant performance is essential for advancing COVID-19 vaccine development.
• Further research is needed to elucidate the efficacy and safety profiles of various adjuvants in the context of coronaviruses.
• This review serves as a foundation for informed adjuvant selection to improve COVID-19 vaccine design.